Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2619-2622

  Danciu, Oana C ^a   Rayani, Shayan ^a   Michals, Edward A ^a   Villano, J Lee ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Bevacizumab; Brain metastasis; CNS; MRI; NSCLC

Indexed keywords

BEVACIZUMAB; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; GADOLINIUM; PEMETREXED; ZOLEDRONIC ACID;

ADULT; ALLELE; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG ACTIVITY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84867990214     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0148-x     Document Type: Article

References (14)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50.
3. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-11.
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-40.
5. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16:269-78.
6. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255-61.
7. Lung NNSC. Panel C: NCCN practice guidelines in oncologyv.3.2011: non small cell lung cancer. 3rd edn.; MS-27, NCCN; 2011.
8. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-51.
9. Larsson HB, Courivaud F, Rostrup E, et al. Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 tesla. Magn Reson Med. 2009;62:1270-81.
10. Neuwelt EA, Barnett PA, Hellstrom KE, et al. Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J Nucl Med. 1994;35:1831-41.
11. De Braganca KC, Janjigian YY, Azzoli CG, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J Neurooncol. 2010;100:443-7.
12. Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest. 1993;91:153-9.
13. Gerstner ER, Duda DG, di Tomaso E, et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009;6:229-36.
14. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510-4.